{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:17:21Z","timestamp":1792124241662,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015515","name":"Kementerian Pendidikan Malaysia","doi-asserted-by":"publisher","award":["MOE 110QR001I5"],"award-info":[{"award-number":["MOE 110QR001I5"]}],"id":[{"id":"10.13039\/501100015515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110-2628-E-007-007"],"award-info":[{"award-number":["110-2628-E-007-007"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["108-2221-E-007-104-MY5"],"award-info":[{"award-number":["108-2221-E-007-104-MY5"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110-2634-F-007-023"],"award-info":[{"award-number":["110-2634-F-007-023"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008070","name":"Department of Medicine, University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX111-11015BI"],"award-info":[{"award-number":["NHRI-EX111-11015BI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jconrel.2022.04.004","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T23:01:14Z","timestamp":1650668474000},"page":"169-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis"],"prefix":"10.1016","volume":"346","author":[{"given":"Hui-Teng","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsi-Chien","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hui","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hua","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Ru","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Hsuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsueh-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Han","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Pu","family":"Juang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ting","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-How","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuei-Liong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Chieh","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.04.004_bb0005","first-page":"96","article-title":"Fibrosis--A common pathway to organ injury and failure","volume":"373","author":"Rockey","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0010","first-page":"684","article-title":"Cellular and molecular mechanisms of renal fibrosis, nature reviews","volume":"7","author":"Liu","year":"2011","journal-title":"Nephrology"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mam.2018.06.003","article-title":"Organ and tissue fibrosis: molecular signals, cellular mechanisms and translational implications","volume":"65","author":"Weiskirchen","year":"2019","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0020","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0025","first-page":"104","article-title":"The global burden of chronic kidney disease: estimates, variability and pitfalls, nature reviews","volume":"13","author":"Glassock","year":"2017","journal-title":"Nephrology"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0030","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev-pathol-020712-163930","article-title":"Host responses in tissue repair and fibrosis","volume":"8","author":"Duffield","year":"2013","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0040","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3389\/fphar.2017.00855","article-title":"Drugs and targets in fibrosis","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0045","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1021\/acs.molpharmaceut.5b00913","article-title":"Dual-functional nanoparticles targeting CXCR4 and delivering antiangiogenic siRNA ameliorate liver fibrosis","volume":"13","author":"Liu","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2015.11.003","article-title":"Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis","volume":"221","author":"Lin Ts","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0055","doi-asserted-by":"crossref","first-page":"894","DOI":"10.7150\/thno.21168","article-title":"Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development","volume":"8","author":"Sung","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0060","article-title":"Sorafenib ameliorates renal fibrosis through inhibition of TGF-beta-induced epithelial-mesenchymal transition","volume":"10","author":"Jia","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0065","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1159\/000447883","article-title":"Sorafenib inhibits renal fibrosis induced by unilateral ureteral obstruction via inhibition of macrophage infiltration","volume":"39","author":"Ma","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0075","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jpba.2009.02.008","article-title":"Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice","volume":"49","author":"Blanchet","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0080","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jconrel.2022.01.033","article-title":"Renal Nano-drug delivery for acute kidney injury: current status and future perspectives","volume":"343","author":"Geo","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0085","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jconrel.2020.02.027","article-title":"Recent advances in nanotechnology-based drug delivery systems for the kidney","volume":"321","author":"Oroojalian","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0090","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jconrel.2020.09.022","article-title":"Kidney-targeted therapies: a quantitative perspective","volume":"328","author":"van Asbeck","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0095","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.1016\/j.biomaterials.2014.04.106","article-title":"Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan","volume":"35","author":"Qiao","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1039\/C7BM00811B","article-title":"Coordination-driven assembly of catechol-modified chitosan for the kidney-specific delivery of salvianolic acid B to treat renal fibrosis","volume":"6","author":"Li","year":"2017","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0105","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1039\/C8BM01297K","article-title":"A stimuli-responsive drug release nanoplatform for kidney-specific anti-fibrosis treatment","volume":"7","author":"Tan","year":"2019","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0110","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jconrel.2011.08.041","article-title":"Imatinib-ULS-lysozyme: a proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases","volume":"157","author":"Dolman","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0115","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/nm.3218","article-title":"Origin and function of myofibroblasts in kidney fibrosis","volume":"19","author":"LeBleu","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2353\/ajpath.2010.090517","article-title":"Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis","volume":"176","author":"Humphreys","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrneph.2014.246","article-title":"Diverse origins of the myofibroblast-implications for kidney fibrosis","volume":"11","author":"Falke","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","article-title":"Decoding myofibroblast origins in human kidney fibrosis","volume":"589","author":"Kuppe","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0135","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2020.01.017","article-title":"Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity","volume":"320","author":"Li","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0140","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2353\/ajpath.2008.080433","article-title":"Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney","volume":"173","author":"Lin","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0145","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0150","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2019.02.049","article-title":"Myofibroblast phenotype and reversibility of fibrosis in patients with end-stage heart failure","volume":"73","author":"Nagaraju","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0155","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0160","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clml.2019.03.011","article-title":"SOHO state of the art updates and next questions: myelofibrosis","volume":"19","author":"Pettit","year":"2019","journal-title":"Clin. Lymphoma. Myeloma Leuk."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0165","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1096\/fj.14-258459","article-title":"Selective delivery of IFN-gamma to renal interstitial myofibroblasts: a novel strategy for the treatment of renal fibrosis","volume":"29","author":"Poosti","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0170","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1073\/pnas.1103573108","article-title":"Targeting kidney mesangium by nanoparticles of defined size","volume":"108","author":"Choi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119368","article-title":"Size and temporal-dependent efficacy of oltipraz-loaded PLGA nanoparticles for treatment of acute kidney injury and fibrosis","volume":"219","author":"Yu","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0180","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/ki.2009.86","article-title":"Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy","volume":"75","author":"Chevalier","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0185","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-018-07858-8","article-title":"The mTORC1\/4E-BP1 axis represents a critical signaling node during fibrogenesis","volume":"10","author":"Woodcock","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0190","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ki.2008.160","article-title":"Activation of Erk1\/2 and Akt following unilateral ureteral obstruction","volume":"74","author":"Rodriguez-Pena","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0195","first-page":"564","article-title":"New insights into sorafenib resistance in hepatocellular carcinoma: responsible mechanisms and promising strategies","volume":"2017","author":"Niu","year":"1868","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.jconrel.2022.04.004_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.154","article-title":"Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation","volume":"4","author":"Chen","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0205","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94979","article-title":"RIPK3 promotes kidney fibrosis via AKT-dependent ATP citrate lyase","volume":"3","author":"Imamura","year":"2018","journal-title":"JCI Insight."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0210","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0215","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.04.004_bb0220","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.addr.2017.07.010","article-title":"Drug targeting to myofibroblasts: implications for fibrosis and cancer","volume":"121","author":"Yazdani","year":"2017","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922001985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922001985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:07:43Z","timestamp":1778674063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922001985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":44,"alternative-id":["S0168365922001985"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.04.004","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}